<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02450799</url>
  </required_header>
  <id_info>
    <org_study_id>ILQ245-P001</org_study_id>
    <secondary_id>UMIN000017727</secondary_id>
    <nct_id>NCT02450799</nct_id>
  </id_info>
  <brief_title>Corrected VA With Long-Term Follow-Up After AcrySof® Intraocular Lens (IOL) Implantation</brief_title>
  <official_title>Corrected VA With Long-Term Follow-Up After AcrySof® IOL Implantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alcon, a Novartis Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alcon Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the long-term visual acuity (VA) with an acrylic IOL
      to a silicone or polymethylmethacrylate (PMMA) IOL in cataract patients. This study will take
      place in Japan.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) at the Long-Term, Post-Implantation Visit</measure>
    <time_frame>Baseline (up to and including 3 months after implantation), long-term post-implantation visit (14-20 years after implantation)</time_frame>
    <description>Measurement of best corrected (with spectacles or other visual corrective devices) visual acuity (at both near and distance). Visual Acuity (VA) is measured in logMAR (logarithm of the minimum angle of resolution). A lower logMAR value indicates better visual acuity. One eye (study eye) contributed to the analysis.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">104</enrollment>
  <condition>Pseudophakia</condition>
  <arm_group>
    <arm_group_label>AcrySof IOL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Acrylic IOL, prior implantation (1994-2000) in one or both eyes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Silicone IOL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Silicone IOL, prior implantation (1994-2000) in one or both eyes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PMMA IOL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PMMA IOL, prior implantation (1994-2000) in one or both eyes</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Acrylic IOL</intervention_name>
    <description>Acrylic IOL for long-term implantation in the cataract patient</description>
    <arm_group_label>AcrySof IOL</arm_group_label>
    <other_name>AcrySof® Model MA30BA</other_name>
    <other_name>AcrySof® Model MA60BM</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Silicone IOL</intervention_name>
    <description>Silicone IOL for long-term implantation in the cataract patient</description>
    <arm_group_label>Silicone IOL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PMMA IOL</intervention_name>
    <description>Polymethylmethacrylate IOL for long-term implantation in the cataract patient</description>
    <arm_group_label>PMMA IOL</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Willing to provide voluntary consent and able to comprehend and sign the informed
             consent form;

          -  Pseudophakic patients implanted with an Acrylic (AcrySof®), PMMA or silicone IOL from
             1994 to 2000;

          -  Clear intraocular media in study eye;

          -  Best‐corrected visual acuity (decimal) within 3 months post-implantation of 0.8
             (decimal VA chart) or more in study eye;

          -  No ocular or systemic condition which may affect visual acuity in study eye;

          -  Other protocol-specified inclusion criteria may apply.

        Exclusion Criteria:

          -  Complications that may impact visual acuity in study eye at the time of the
             prospective visit, such as glaucoma, diabetic retinitis, ocular inflammatory disease,
             retinal detachment, and others as specified in the protocol;

          -  Previous refractive surgery in study eye;

          -  Previous IOL exchange in study eye;

          -  Other protocol-specified exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Group Manager, Clinical Dev.</last_name>
    <role>Study Director</role>
    <affiliation>Alcon Japan, Ltd.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Japan</country>
  </removed_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 19, 2015</study_first_submitted>
  <study_first_submitted_qc>May 19, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 21, 2015</study_first_posted>
  <results_first_submitted>October 17, 2016</results_first_submitted>
  <results_first_submitted_qc>October 17, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 9, 2016</results_first_posted>
  <last_update_submitted>October 17, 2016</last_update_submitted>
  <last_update_submitted_qc>October 17, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 9, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pseudophakia</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited from 11 study centers located in Japan.</recruitment_details>
      <pre_assignment_details>Of the 104 enrolled, 6 subjects were exited as screen failures and deemed ineligible for participation. This reporting group includes all eligible subjects (98).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>AcrySof</title>
          <description>Acrylic IOL, prior implantation (1994-2000) in one or both eyes</description>
        </group>
        <group group_id="P2">
          <title>Silicone</title>
          <description>Silicone IOL, prior implantation (1994-2000) in one or both eyes</description>
        </group>
        <group group_id="P3">
          <title>PMMA</title>
          <description>Polymethylmethacrylate (PMMA) IOL, prior implantation (1994-2000) in one or both eyes</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="37"/>
                <participants group_id="P3" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="37"/>
                <participants group_id="P3" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>This analysis population includes all subjects who used the study devices and underwent the long-term post-implantation visit examination (Safety Set).</population>
      <group_list>
        <group group_id="B1">
          <title>AcrySof</title>
          <description>Acrylic IOL, prior implantation (1994-2000) in one or both eyes</description>
        </group>
        <group group_id="B2">
          <title>Silicone</title>
          <description>Silicone IOL, prior implantation (1994-2000) in one or both eyes</description>
        </group>
        <group group_id="B3">
          <title>PMMA</title>
          <description>Polymethylmethacrylate IOL, prior implantation (1994-2000) in one or both eyes</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="31"/>
            <count group_id="B2" value="37"/>
            <count group_id="B3" value="30"/>
            <count group_id="B4" value="98"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>subjects</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;70 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥70 and ≤79 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥80 and ≤89 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;90 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>subjects</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) at the Long-Term, Post-Implantation Visit</title>
        <description>Measurement of best corrected (with spectacles or other visual corrective devices) visual acuity (at both near and distance). Visual Acuity (VA) is measured in logMAR (logarithm of the minimum angle of resolution). A lower logMAR value indicates better visual acuity. One eye (study eye) contributed to the analysis.</description>
        <time_frame>Baseline (up to and including 3 months after implantation), long-term post-implantation visit (14-20 years after implantation)</time_frame>
        <population>This analysis population includes all subjects who used the study devices and have data after implantation of study devices (Full Analysis Set).</population>
        <group_list>
          <group group_id="O1">
            <title>AcrySof</title>
            <description>Acrylic IOL, prior implantation (1994-2000) in one or both eyes</description>
          </group>
          <group group_id="O2">
            <title>Silicone</title>
            <description>Silicone IOL, prior implantation (1994-2000) in one or both eyes</description>
          </group>
          <group group_id="O3">
            <title>PMMA</title>
            <description>Polymethylmethacrylate IOL, prior implantation (1994-2000) in one or both eyes</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) at the Long-Term, Post-Implantation Visit</title>
          <description>Measurement of best corrected (with spectacles or other visual corrective devices) visual acuity (at both near and distance). Visual Acuity (VA) is measured in logMAR (logarithm of the minimum angle of resolution). A lower logMAR value indicates better visual acuity. One eye (study eye) contributed to the analysis.</description>
          <population>This analysis population includes all subjects who used the study devices and have data after implantation of study devices (Full Analysis Set).</population>
          <units>logMAR</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.06" spread="0.07"/>
                    <measurement group_id="O2" value="-0.09" spread="0.07"/>
                    <measurement group_id="O3" value="-0.07" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.08"/>
                    <measurement group_id="O2" value="0.04" spread="0.06"/>
                    <measurement group_id="O3" value="-0.01" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events (AEs) were collected for the duration of a subject’s participation in the study; retrospectively 14 to 20 years and prospectively for a single visit. This analysis group includes all subjects who used the study devices and underwent the long-term post-implantation visit examination. Ocular adverse events are presented for both study eye and non-study eye combined.</time_frame>
      <desc>An AE was defined as any untoward medical occurrence, unintended disease or injury, or untoward clinical signs in subjects, whether or not related to the investigational medical device (test/control article or procedure). AEs are reported retrospectively (onset between Baseline (defined as the period within 3 months after surgery) and Informed Consent acquisition) and prospectively (onset after Informed Consent acquisition).</desc>
      <group_list>
        <group group_id="E1">
          <title>AcrySof (Retrospective)</title>
          <description>Subjects with prior implantation of acrylic IOL who experienced an AE related to decrease of BCVA in the study eye</description>
        </group>
        <group group_id="E2">
          <title>Silicone (Retrospective)</title>
          <description>Subjects with prior implantation of Silicone IOL who experienced an AE related to decrease of BCVA in the study eye</description>
        </group>
        <group group_id="E3">
          <title>PMMA (Retrospective)</title>
          <description>Subjects with prior implantation of PMMA IOL who experienced an AE related to decrease of BCVA in the study eye</description>
        </group>
        <group group_id="E4">
          <title>AcrySof (Prospective)</title>
          <description>Subjects with prior implantation of acrylic IOL who experienced an AE with onset after the Informed Consent acquisition</description>
        </group>
        <group group_id="E5">
          <title>Silicone (Prospective)</title>
          <description>Subjects with prior implantation of Silicone IOL who experienced an AE with onset after the Informed Consent acquisition</description>
        </group>
        <group group_id="E6">
          <title>PMMA (Prospective)</title>
          <description>Subjects with prior implantation of PMMA IOL who experienced an AE with onset after the Informed Consent acquisition</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA/J (19.0)</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>posterior capsule opacification</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Sponsor reserves the right of prior review of any publication or presentation of information related to the study.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Phase IV, Clinical and Regulatory Affairs, Alcon Japan</name_or_title>
      <organization>Alcon, A Novartis Division</organization>
      <phone>1-888-451-3937</phone>
      <email>alcon.medinfo@alcon.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

